Intravenous Immunoglobulin Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection: A Retrospective Study of 10 Patients and Review of the Literature
Authors:
- Olivier HermineOHOlivier Hermine
- Luc MouthonLMLuc Mouthon
- For The Groupe D'Experts de L'Assistance Publique-Hopitaux de ParisFPFor The Groupe D'Experts de L'Assistance Publique-Hopitaux de Paris
- G. LoicGLG. Loic
- Bussel AnnetteBABussel Annette
Open Access
- 12 December 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 56 (7) , 968-977
Abstract
Background. We evaluated the efficacy of intravenous immunoglobulin (IVIG) therapy in patients with pure red cell aplasia (PRCA) related to human parvovirus B19 (HPV-B19) infection. Methods. We retrospectively reviewed all HPV-B19 PRCA cases treated with IVIG between January 2000 and December 2005 in the Assistance Publique-Hôpitaux de Paris hospitals and reviewed all cases of HPV-B19 PRCA cases treated with IVIG in the literature. Results. Among our 36 patients, PRCA was confirmed in 22, including 10 with proven HPV-B19 infection. Nine patients were immunocompromised, including 4 who had undergone transplant. All patients had severe anemia (mean hemoglobin level, 5.0 ± 1.9 g/dL). Seven patients who underwent bone-marrow aspiration had positive HPV-B19 polymerase chain reaction (PCR) results at diagnosis. Patients received a mean of 2.7 ± 2.1 IVIG courses (1.3 ± 0.5 g/kg/course). Hemoglobin level was corrected in 9 of the 10 patients within a mean of 80 ± 54 days. The only nonresponsive patient had underlying myelodysplasia. Blood HPV-B19 PCR results were negative from 35 to 159 days after treatment. Four patients showed side effects of IVIG treatment: acute reversible renal failure (n = 2) and pulmonary edema (n = 2). Among 133 patients with HPV-B19 PRCA who received IVIG (our 10 patients and 123 from the literature), 63 had undergone solid-organ transplant and 39 had human immunodeficiency virus infection. Hemoglobin level was corrected after the first IVIG course in 124 patients (93%); disease relapsed in 42 (33.9%), at a mean of 4.3 months. Conclusions. IVIG therapy appears to be effective in the short term in immunocompromised patients with HPV-B19 PRCA.Keywords
This publication has 28 references indexed in Scilit:
- Historical review. The light and shadow of Paul Kaznelson: his life and contribution to hematologyAnnals of Hematology, 2008
- Seroprevalence of parvovirus B19 in the German populationEpidemiology and Infection, 2008
- Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasiaAutoimmunity Reviews, 2005
- Pure Red Cell Aplasia Associated with Parvovirus B19 Infection in T-large Granular Lymphocyte LeukemiaLeukemia & Lymphoma, 2001
- Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimusAmerican Journal of Kidney Diseases, 1999
- Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: Use of intravenous immunoglobulin?A report of eight patientsAmerican Journal of Hematology, 1999
- Red cell aplasia caused by parvovirus B19 in AIDS: use of i.v. immunoglobulinAnnals of Hematology, 1997
- Parvovirus B19 infection and hematopoiesisBlood Reviews, 1995
- Pure Red-Cell Aplasia of 10 Years' Duration Due to Persistent Parvovirus B19 Infection and Its Cure with Immunoglobulin TherapyNew England Journal of Medicine, 1989
- Acquired pure red cell aplasiaAmerican Journal of Hematology, 1987